Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Want to see DNTH full AI Analyst Report?
DNTH Stock Chart & Stats
$93.26
$0.37(1.44%)
At close: 4:00 PM EST
$93.26
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$16.64 - $96.50
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$4.51B
Enterprise Value$2.79B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$1.36M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 06, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding54,666,233
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue2.09K
Enterprise Value/Gross Profit2.22K
Enterprise Value/Ebitda-257.10
Forecast
1Y Price Target
$130.63Price Target Upside40.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.74
Revenue Forecast (FY)$1.18M
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway And Low LeverageA pro forma cash balance of roughly $1.2B, supported by a large public offering, funds multiple late-stage and early-stage clinical programs through ~2030. This materially reduces near-term financing pressure, preserves strategic optionality for partnerships, and allows sustained investment in trials and manufacturing capacity.
Encouraging Phase 3 Interim Responder DataA 75% responder rate in the first 40 patients of the CAPTIVATE Phase 3 interim analysis materially de-risks the claseprubart program. Robust early efficacy can shorten development timelines, strengthen labeling and commercial positioning, and enhance partnering or reimbursement prospects if sustained in larger cohorts.
Very High Gross Profit Margins On Reported RevenueNear-100% gross margins reflect the high-margin nature of biologic revenues and favorable unit economics if commercialized. Durable high gross margins would support attractive long-term profitability once fixed R&D and SG&A leverage is achieved, and make future products more cash-generative post-launch.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent and rising operating and free cash flow deficits mean the company consumes cash to fund development. Even with current runway, sustained burn increases reliance on capital markets or deals, risks dilution, and constrains flexibility to add programs or absorb development delays without altering strategy.
Deep And Widening Operating LossesWidening EBIT/EBITDA losses show the company remains in heavy investment mode with no near-term earnings conversion. Persistent operating deficits reduce resilience to adverse trial outcomes, may force reprioritization of pipeline assets, and heighten dependency on external funding or partner transactions.
Volatile, Small Revenue BaseA small and volatile revenue history indicates limited commercial traction and reliance on future approvals for scale. This amplifies binary clinical risk: disappointing trial results or regulatory delays would quickly undermine revenue prospects and make long-term cash generation uncertain.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $16.64 and its highest was $96.50 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $4.51B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on May 05, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.072 by $0.222.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 54,666,233 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.072. Following the earnings report the stock price went up 0.199%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$130.63 (40.07% Upside)
$130.63 (40.07% Upside)
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
-1.78%
Trailing 12-Months
Asset Growth
257.70%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and inflammatory conditions. The company's pipeline includes DNTH103, an investigational drug presently undergoing Phase 1 clinical assessment in patients diagnosed with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was established in 2015 and operates from its headquarters in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$130.63
▲(40.07% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.13% Insiders
24.04% Mutual Funds
55.84% Other Institutional Investors
10.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---